Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20131026 | 1.00 | HTR2B (1.00) | HTR2BLMNAMAPTTP53ALDH1A1 | |
| SCHEMBL17115697 | 1.00 | HTR2B (1.00) | HTR2BLMNAMAPTTP53ALDH1A1 | |
| SCHEMBL20131087 | 0.91 | HTR2B (0.84) | HTR2BLMNAMAPTTP53ALDH1A1 | |
| SCHEMBL17115720 | 0.91 | HTR2B (0.84) | HTR2BLMNAMAPTTP53ALDH1A1 | |
| SCHEMBL15613076 | 0.89 | HTR2B (0.80) | HTR2BLMNAMAPTTP53ALDH1A1 | |
| SCHEMBL17115715 | 0.88 | HTR2B (0.79) | HTR2BLMNAMAPTTP53ALDH1A1 | |
| SCHEMBL17115708 | 0.88 | HTR2B (0.78) | HTR2BLMNAMAPTTP53ALDH1A1 | |
| SCHEMBL17115717 | 0.87 | HTR2B (0.77) | HTR2BLMNAMAPTTP53ALDH1A1 | |
| SCHEMBL17115716 | 0.87 | HTR2B (0.77) | HTR2BLMNAMAPTALDH1A1KMT2A | |
| SCHEMBL17109112 | 0.87 | HTR2B (0.77) | HTR2BLMNAMAPTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4493694-A1 | MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2025-01-22 | — | — | EP | claimed |
| CN-119032175-A | Modified spacer oligomers and methods of use thereof | 阿利戈斯治疗公司 | 2024-11-26 | — | — | CN | claimed |
| US-20240118278-A1 | HBV DIAGNOSTIC, PROGNOSTIC, AND THERAPEUTIC METHODS AND PRODUCTS | ABBOTT LABORATORIES | 2024-04-11 | — | — | US | claimed |
| WO-2024059692-A1 | HBV DIAGNOSTIC, PROGNOSTIC, AND THERAPEUTIC METHODS AND PRODUCTS | ABBOTT LABORATORIES (US) | 2024-03-21 | — | — | WO | claimed |
| WO-2023177808-A1 | MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | claimed |
| EP-4121533-A1 | MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES AND USES THEREOF | Aligos Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | claimed |
| CN-115485384-A | Modified short interfering nucleic acid (siNA) molecules and uses thereof | 阿利戈斯治疗公司 | 2022-12-16 | — | — | CN | claimed |
| US-20220364096-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | US | claimed |
| EP-3976056-A2 | MODIFIED GAPMER OLIGONUCLEOTIDES AND METHODS OF USE | Aligos Therapeutics, Inc. (US) | 2022-04-06 | — | — | EP | claimed |
| US-20260098090-A1 | FUSIONS WITH CD8 ANTIGEN BINDING MOLECULES FOR TREATING CHRONIC VIRAL INFECTION | ASHER BIOTHERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260028603-A1 | ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME | PRECISION BIOSCIENCES, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260002157-A1 | MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4667499-A2 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | Gilead Sciences, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250368996-A1 | MODIFIED ANTISENSE OLIGONUCLEOTIDES FOR TREATING HEPATITIS B VIRUS | ALIGOS THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| EP-3990476-A1 | FLT3L-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20220125884-A1 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. | 2022-04-28 | — | — | US | disclosed |
| WO-2022087149-A2 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| EP-3976056-A2 | MODIFIED GAPMER OLIGONUCLEOTIDES AND METHODS OF USE | Aligos Therapeutics, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114245807-A | FLT3L-FC fusion proteins and methods of use | 吉利德科学公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20220049021-A1 | FLT3L-Fc FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098090-A1 | FUSIONS WITH CD8 ANTIGEN BINDING MOLECULES FOR TREATING CHRONIC VIRAL INFECTION | CD4, HAVCR2, CD81 | HTR2B 3352/4885LMNA 3476/4885MAPT 2408/4885 |
| US-20260002157-A1 | MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF | SRRT, SLIRP, FBL | HTR2B 4760/4885LMNA 908/4885MAPT 3382/4885 |
| US-20220364096-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | HTR2B 3489/4885LMNA 737/4885MAPT 3425/4885 |
| US-20250368996-A1 | MODIFIED ANTISENSE OLIGONUCLEOTIDES FOR TREATING HEPATITIS B VIRUS | HAVCR2, SNRPB2, NSUN2 | HTR2B 2876/4885LMNA 3128/4885MAPT 4178/4885 |
| US-20260028603-A1 | ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME | HAVCR2, PNP, ADAR | HTR2B 1377/4885LMNA 1428/4885MAPT 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.